glp-1 ibd 🚨 RA use in is rising fast In this 14-month repeated survey of patients with IBD: 📈 GLP-1 RA use rose 5-fold ⚖️ Median BMI fell from 35.3 → 31.2 Frontiers | GLP-1 receptor agonists

Experiments were repeated three times and error bars represent s.e.m

Building upon the growing recognition of cardiometabolic organ protection as a central therapeutic goal, incretin-based therapies have reshaped the management of type 2 diabetes and obesity, extending their clinical relevance far beyond glycemic control

Use a New Needle Each Time: Reusing needles can dull them and introduce bacteria

Sinclair: Invex therapeutics, company director with salary and stock options (2019, 2020)

Collectively, we update translational concepts of GIP and GLP1 action, while highlighting gaps, areas of uncertainty and controversies meriting ongoing investigation